Scientists don’t yet know whether the process of mRNA translation represents a therapeutic vulnerability in bladder cancer. The lab of Dr. Andrew Hsieh at Fred Hutchinson Cancer Center sought to investigate this question using patient-derived xenograft, or PDX, models derived from bladder cancer patients.
The Hsieh Lab was eager to begin their project but had no experience in developing PDX lines.
The team purchased six models from the Jackson Laboratory and acquired lines developed at the University of Washington, and they sought the help of the Preclinical Modeling core’s PDX team to develop them. With the help of PDX lead Elizabeth Cromwell, Hsieh’s team was able to resurrect the models they purchased and acquired, passage them, validate them and subsequently use them for preclinical trials. Throughout the project, Cromwell provided Hsieh Lab members with invaluable instruction on the intricacies of working with PDX models.